The combined statutory net income, excluding intercompany dividends and surplus note interest, and capital and
surplus of the Company’s U.S. domiciled statutory insurance subsidiaries is as follows:
|
Years Ended December 31,
|
|
2023
|
2022
|
2021
|
Property and Casualty ("P&C") companies |
$529.4
|
$283.5
|
$468.0
|
Life and Health ("L&H") companies |
13.7
|
20.0
|
18.6
|
Total statutory net income (1) |
$543.1 |
$303.5 |
$486.6 |
(1)There was no statutory net income for the years ended December 31, 2022 and 2021 from the insurance entities included in the disposed Global Preneed business due to the August 2021 sale.
|
December 31,
|
|
2023
|
2022
|
P&C companies |
$1,461.4
|
$1,472.2
|
L&H companies |
87.6
|
80.2
|
Total statutory capital and surplus(1) |
$1,549.0
|
$1,552.4
|
(1)There was no statutory capital and surplus as of December 31, 2022 and 2021 from the insurance entities included in the disposed Global Preneed business.
The Company also has non-insurance subsidiaries and foreign insurance subsidiaries that are not subject to SAP. The
statutory net income and statutory capital and surplus amounts presented above do not include non-insurance
subsidiaries and foreign insurance subsidiaries in accordance with SAP.
Insurance enterprises are required by state insurance departments to adhere to minimum risk-based capital ("RBC") requirements developed by
the NAIC. The Company's insurance subsidiaries expect to exceed minimum RBC requirements as of December 31, 2023. In addition, all of our rated insurances subsidiaries currently maintain an A.M. Best financial strength rating of A.
The payment of dividends to the Company by any of the Company’s regulated U.S domiciled insurance subsidiaries in
excess of a certain amount (i.e., extraordinary dividends) must be approved by the subsidiary’s domiciliary
jurisdiction department of insurance. Ordinary dividends, for which no regulatory approval is generally required,
are limited to amounts determined by a formula, which varies by jurisdiction. The formula for the majority of the
jurisdictions in which the Company’s subsidiaries are domiciled is based on the prior year’s statutory net income or
10% of the statutory surplus as of the end of the prior year. Some jurisdictions limit ordinary dividends to the
greater of these two amounts, others limit them to the lesser of these two amounts and some jurisdictions exclude
prior year realized capital gains from prior year net income in determining ordinary dividend capacity. Some
jurisdictions have an additional stipulation that dividends may only be paid out of earned surplus. If insurance
regulators determine that payment of an ordinary dividend or any other payments by the Company’s insurance
subsidiaries to the Company (such as payments under a tax sharing agreement or payments for employee or other
services) would be adverse to policyholders or creditors, the regulators may block such payments that would
otherwise be permitted without prior approval. Based on the dividend restrictions under applicable laws and
regulations, the maximum amount of dividends that the Company’s U.S domiciled insurance subsidiaries could pay to
the Company in 2024 without regulatory approval is $592.4 million. No assurance can be given that there will not be
further regulatory actions restricting the ability of the Company’s insurance subsidiaries to pay dividends.